CytoSorbents Announces $6.25 Million Financing and Restructuring of Avenue Capital Credit Facility

CytoSorbents Corporation (NASDAQ: CTSO) has announced a $6.25 million common stock financing through a registered direct offering. The deal includes a $4.0 million cash component led by existing shareholders and management, alongside the issuance of common stock to satisfy $2.25 million of debt owed to Avenue Capital Group. As part of this financing, the company is restructuring its credit facility with Avenue Capital, resulting in a total debt reduction of $5.25 million down to $12.25 million. This move is expected to save the company approximately $0.7 million in interest expenses over the next 12 months. Additionally, the maturity date for the remaining debt has been extended to July 1, 2028, with an extension of the interest-only period through March 31, 2028.

By Cytosorbents Corp · PR Newswire ·

CytoSorbents Announces $6.25 Million Financing and Restructuring of Avenue Capital Credit Facility

Topics: Common Stock Issuance Debt Reduction Financing Registered Direct Offering

Read the full article at PR Newswire

More World news